About the Company
Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma's lead product candidate, OC-01 (varenicline) nasal spray, a highly selective cholinergic agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. In pre-clinical and clinical studies, OC-01 (varenicline) nasal spray was shown to have a novel mechanism of action via activation of the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the lacrimal functional unit.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
62
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $OYST News
Oyster Point Pharma Announces Expanded Patient Access to TYRVAYA®
Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discovery, development and ...
IPO Outlook For The Week: Chinese Media, Chinese Real Estate, Dry-Eye Therapy
Oyster Point Pharma, Inc. (NASDAQ: OYST) will issue 5 million shares between $16 and $18 Thursday on the Nasdaq. The offering represents 24.3% of outstanding shares and is expected to raise about ...
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
Nadia K. Waheed, MD, MPH, Appointed Chief Medical Officer; Peter K. Kaiser, MD, to Become Chief Development Officer; Andrea Gibson, PhD, Named ...
Oyster Point Pharma to Present Data at the American Academy of Optometry Annual Meeting 2021
PRINCETON, N.J., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of ...
As biotech vacancies hit 20%, oversupply of space could crunch crossover developers
The biotech real estate vacancy rate in Bay Area reached 20% as new projects come online and sublease space hits market.
Viatris (VTRS) to Report Q4 Earnings: Is a Beat in Store?
Viatris Inc. Price, Consensus and EPS Surprise Viatris ... VTRS completed the acquisitions of Oyster Point Pharma and Famy Life Sciences to establish a new division, Viatris Eye Care.
Peter J Barris's Net Worth
Who is Peter J Barris? Peter J Barris has an estimated net worth of $2.53 Billion. This is based on reported shares across multiple companies, which include GLU MOBILE INC, SUNESIS PHARMACEUTICALS ...
LIFE aTyr Pharma, Inc.
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is ...
General Oyster Inc 3224
We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished ...
ASMB Assembly Biosciences, Inc.
Assembly Biosciences, Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company’s ...
Vincerx Pharma Inc Ordinary Shares VINC
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Lantern Pharma Inc. (LTRN)
Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...
Loading the latest forecasts...